Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract B046: Homologous recombination DNA repair dependent survival associations in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis consortium study
Weir, Ashley , Talhouk, Aline , Anglesio, Mike S., Garsed, Dale W. , Harris, Holly H., Schildkraut, Joellen M. , Goode, Ellen L. , Huntsman, David G. , Doherty, J.A. , Anglesio, Michael S. , Anglesio, Michael S , Garsed, Dale W , Chiu, Derek S , Anglesio, Mike S., DeFazio, Anna , Harris, Holly H., Berchuck, Andrew , Pharoah, Paul D.P. , Bowtell, David D.L. , Davidson, N. , Köbel, Martin , Ramus, Susan J.

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: B046-B046

10.1158/1538-7445.ovarian25-b046 Get It

Abstract Despite homologous recombination (HR) deficiency being an important predictor of survival in high-grade serous ovarian carcinoma (HGSC), its status is rarely considered in large-scale studies of prognostic signatures and biomarkers. We sought to develop a gene expression-based classifier of HR deficient (HRD) HGSCs, suitable for archival FFPE tumor samples, to determine whether established prognostic markers were dependent on HR status. Using 361 HGSCs from The Cancer Genome Atlas (TCGA) where HR status was defined by the genomic gold standard, a HRD score, we trained and tested a ridge penalized logistic regression model. This 218-gene mRNA expression signature was then applied in 6002 HGSCs from the Ovarian Tumor Tissue Analysis (OTTA) consortium to predict the probability of a sample being HRD. In this large cohort of FFPE samples, we sought to understand the relationship between HR and overall survival. Applying Kaplan-Meier analyses and multivariate Cox proportional hazard regression modelling, adjusting for age and stratified by stage and study, we examined the relationship between HR status and the PrOTYPE subtype, SPOT prognostic score and other known prognostic markers in HGSC. Our machine learning model was 84% accurate in a held-out subset of the TCGA (n=73). Of the 6002 OTTA HGSCs, 40.4% were predicted to be HRD. These cases were significantly younger, were enriched for early stage (FIGO I/II) and had improved outcomes when compared to HR proficient (HRP) cases (hazard ratio [HZR]=0.71, 95% confidence interval [CI]=0.66-0.76, p<2x10-16). A linear increase in survival time was observed as the probability of a sample being HRD increased. HGSCs with >75% likelihood of being HRD had a median 5-year survival of 49.3% (95%CI=46.2-52.6%) which was a 17.7% increase from those with <25% likelihood. Both PrOTYPE and SPOT were significantly associated with survival, independent of HR status (p<2x10-16 and p<2x10-16 respectively). Notably the probability of being HRD was negatively correlated with an unfavorable SPOT score (R=-0.32, p<2x10-16), suggesting that SPOT partially captures the survival advantage of HR deficiency. Several individual biomarkers, assessed in 1248 to 2858 cases, showed HR dependent survival associations. HRD HGSCs with high GMNN expression had significantly improved, long-term outcomes (4-10years, HZR=0.39, 95%CI=0.20-0.78, p=0.01), and may be a marker of exceptional survival, while AR negative HRD cases had poorer outcomes, earlier in disease progression (0-4years, HZR=1.43, 95%CI=1.03-1.98, p=0.03). Significantly poorer prognoses were observed in HRP cases expressing PTEN (HZR=1.39, 95%CI=1.04-1.87, p=0.03), and in HRD cases with high expression of MyD88 (HZR=1.21, 95%CI=1.01-1.45, p=0.04). RB1 and FOXJ1 protein expression, and CD8+ T cell abundance were prognostic irrespective of HR status. Our study contributes to understanding the association between HR and HGSC survival in a statistically powered cohort and demonstrates heterogeneity in outcomes through clinically relevant prognostic signatures and biomarkers. Citation Format: Ashley L. Weir, Derek Chiu, Aline Talhouk, Mike S. Anglesio, Dale W. Garsed, Anna DeFazio, Holly H. Harris, Joellen M. Schildkraut, Andrew Berchuck, Ellen L. Goode, Paul D.P. Pharoah, David Huntsman, David Bowtell, Jen A. Doherty, Nadia M. Davidson, Martin Köbel, Susan J. Ramus. Homologous recombination DNA repair dependent survival associations in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis consortium study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B046.
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children
Almond, Christopher S. , Alejos, Juan , Ameduri, Rebecca , Barkoff, L., Barnes, Aliessa, Butto, Arene , Carlo, Waldemar F. , Chrisant, Maryanne , Dreyer, William J. , Everitt, Melanie D. , Gonzales, S., Hollander, Seth A. , Kindel, Steven J. , Klein, Gloria L., Lamour, Jacqueline M. , Lee, Joanne , Lü, Minmin , Lytrivi, Irene D. , Miyamoto, Shelley D. , Pahl, Elfriede , Peng, David M. , Sutcliffe, David , Ybarra, A., Zangwill, Steven , Rossano, Joseph W. , Investigators, TEAMMATE Trial, Choi, Jua , Wilber, Jared, Sutherland, Scott M. , Feng, Dana, Lagerborg, Kendra, Burns, Julia, Nikolli, Kledja, Twombly, Adrianna, Massey, Linda K., Wartick, Jennifer, Yohannes, Kifle, Gupta, Akanksha , Major, Melissa , Blume, Elizabeth D. , Esteso, Paul , VanderPluym, Christina , Bastardi, Heather , MacLean, Matthew T. , Haschke, Paul, Gibbons, Taylor , Vu, Courtney , Reilly, Sydney, Ha, Lynne, Boyle, Carley, Robie, Sharon L., Ogata, Kay, Knecht, Carlos, Browne, Lorna P. , Malone, LaDonna J. , Gordon, Megyn, Molina, Kimberly , Cabrera, Antonio G. , Lambert, Linda, Fullerton, Chase, Thompson, Kate J., Cardon, Michelle, Timmer, Amanda, Nelson, Michelle , Ramstack, Dani, Heyrend, Carly, Benefield, Emily C., Roberson, Teresa, Butts, Ryan J. , Martinez, Maria , Pottorre, Simi, Burgardt, Laura, Armstrong, Blake, Zamberlan, M. , McCormick, Amanda D. , Bartsch, Jaynee, Mahle, William T. , Burnett, Meilssa, Pietra, Biagio A. , Breault, Leah, Friedland‐Little, Joshua , Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Garcia, Allison, Addonizio, Linda J. , Repp, Arielle, Cornelius, C.E. , Abraham, Margaret, Rose-Felker, Kristen, Moninger, Allison, Huston, Allison, Berman, Pamela, Ploutz, Michelle , Wisotzkey, Bethany , Grohall, Stacey, Colon, April, Churosh, Jenny, Cordova, Renee, Smith, Paulette, Kornetsky, Susan , Mitchell, Anna, Alderson, Daniel, Dominguez, R Blanco, Gawlowicz, Kennan, Lipsitz, Stuart R. , Eisen, Howard J. , Jeewa, Aamir , Uber, Patricia A., Thakar, Rahul, Ellsworth, Darrell L. , McCormick, A , Peng, D M , Daly, Kevin P , Albers, Erin L. , Auerbach, Scott R. , Bock, Matthew J. , Castleberry, Chesney , Deshpande, Shriprasad R. , Feingold, Brian , Lal, Ashwin K. , Ryan, Thomas D. , Singh, Tajinder P. , Su, Jennifer A. , Sleeper, Lynn A. , Investigators, TEAMMATE Trial, Wilber, Jared, Nikolli, Kledja, Massey, Linda, Wartick, Jennifer, Major, Melissa, MacLean, Matthew, Lee, JungWoo, Joong, Anna , Reilly, Sydney, Kuhn, Michael, Ogata, Kay, Knecht, Carol, Gordon, Megyn, Hansen, Lisa, May, Lindsay J. , Lambert, Linda, Fullerton, Chase, Thompson, Kate, Timmer, Amanda, Heyrend, Carly, Martinez, Maria, Schumacher, Kurt R. , Lim, Heang M. , Bartsch, Jaynee, Burnett, Meilssa, Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Repp, Arielle, Bansal, Neha , Hsu, Daphne T. , Cornelius, Chelsea, Padilla, Luz A. , Churosh, Jenny, Cordova, Renee, Mitchell, Anna, Alderson, Daniel, Dominguez, Robleinscky, KOBASHIGAWA, JON A. , Wightman, Aaron G.

Mayo Clinic

JAMA | September 17, 2025 | Volume: 334 | Issue: 15 | Pages: 1339

10.1001/jama.2025.14338 | PMID 40960806 Get It

ImportanceStudies suggest that everolimus may reduce the risk of rejection, cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD), and cytomegalovirus (CMV) after heart transplant. Everolimus use is controversial because of data demonstrating higher infection deaths when everolimus is introduced de novo after transplant. It is unclear whether everolimus is safe and effective when initiated at 6 months posttransplant in children, a population in which median graft survival is limited to 15 years and randomized clinical trials are lacking.ObjectiveTo evaluate the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant.Design, Setting, and ParticipantsMulticenter, randomized, open-label, clinical trial enrolling 211 patients who were alive 6 months after pediatric heart transplant at 25 US sites from February 2018 to August 2020. The last date of follow-up was April 17, 2023.InterventionsParticipants were randomized to receive everolimus and low-dose tacrolimus (n = 107) or standard-dose tacrolimus and mycophenolate mofetil (n = 104) for 30 months.Main Outcomes and MeasuresThe primary efficacy end point was the MATE-3 score at 30 months, a validated composite ordinal end point including acute cellular rejection, CAV, and CKD. The primary safety end point was the MATE-6 score, encompassing the MATE-3 score plus antibody-mediated rejection, infection, and posttransplant lymphoproliferative disorder.ResultsAmong 211 children randomized, the mean age was 8.2 (SD, 6.3) years, 97 (46%) underwent transplant for congenital heart disease, and 49 (23%) were treated for rejection before 6 months. At 30 months, the mean MATE-3 score did not differ between the 2 treatment groups (mean difference, −0.32; 95% CI, −0.90 to 0.20; P = .16). The mean MATE-6 score was no higher in the everolimus group than in the mycophenolate group (baseline-adjusted mean difference, −0.40; 95% CI, −1.81 to 0.93), meeting the success criterion for safety (noninferiority margin <3). There were no differences in graft survival, MATE-free survival, or freedom from any individual MATE. Everolimus was associated with greater improvement in estimated glomerular filtration rate at 12 months (mean difference, 10.5 mL/min/1.73 m2; 95% CI, 1.09-19.91 mL/min/1.73 m2) and a lower incidence of CMV infection (hazard ratio, 0.50; 95% CI, 0.26-0.93).Conclusions and RelevanceAmong 6-month pediatric heart transplant survivors, everolimus and low-dose tacrolimus did not differ from tacrolimus and mycophenolate in preventing the composite of cellular rejection, CAV, and CKD at 30 months. However, everolimus and low-dose tacrolimus appear to be safe based on the total burden of 6 MATEs and may be associated with improved kidney function and less CMV infection.Trial RegistrationClinicalTrials.gov Identifier: NCT03386539
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Janelidze, Shorena, Bali, Divya , Dolado, Anna Orduña , Binette, Alexa Pichet , Rahmouni, Nesrine , Blennow, Kaj, Doré, Vincent , Feizpour, Azadeh , Rowe, Christopher C., Villeneuve, Sylvia , Petersen, Ronald C., Jack, Clifford R. , Groups, ADNI, ALFA, and PREVENT-AD Study, Adegoke, Olusegun, Hussen, Kedir Adem, Aisen, Paul, Ajayi, Adeyinka, Amaza, Hannatu, Apostolova, Liana G. , Ashford, Miriam T. , Ayo, Omobolanle, Bernard, Marie , Bernhardt, Haley, Boatwright, Virginia, Borowski, Bret, Brylska, Magdalena, Buckholtz, Neil, Cabrera, Yuliana, Cairns, Nigel J. , Carrillo, Maria, Choe, Mark, Clanton, Taylor, Conti, Cat, Craft, Hannah, Crawford, Karen , DeCarli, Charles , Benedetto, Joseph Di, Diaz, Adam , Drake, Erin, Faber, Kelley, Felmlee, Joel P. , Fidell, Andrea, Flenniken, Derek , Fockler, Juliet , Forghanian-Arani, Arvin, Frank, R.T., Franklin, Erin , Glittenberg, Matt, Gunter, Jeff, Guzmán, Vanessa , Harvey, Danielle, Hedberg, Caitie, Hergesheimer, Lindsey, Hoang, Isabella, Jackson, Jonathan , Jagust, William, Jahanshad, Neda , Jenkins, Cecily, Jiménez, Gustavo , Jin, Chengshi , Kachaturian, Zaven, Kaddurah-Daouk, Rima, Kantarci, Kejal, Karlawish, Jason , Khachaturian, Zaven S., Knaack, Alexander , Korecka, Magdalena , Kormos, Adrienne, Germano, Kaori Kubo, Kwang, Winnie, Lacy, Kaci, Landau, Susan, Lopresti, Brian J. , Magana, Fabiola, Mahboubi, Payam, Malone, Ian G., Masliah, Eliezer , Masterman, Donna, Matoush, Leonard, Miller, Melanie J. , Molchan, Susan, Montine, Tom, Moore-Weiss, John, Neu, Scott, Nosheny, Rachel L. , Ogwang, Sheila, Okonkwo, Ozioma, Parkins, Shaniya, Perrin, Richard J. , Petersen, Ronald, Pizzola, Jeremy, Potter, Zoë, Potter, William Z., Rafii, Michael, Raman, Rema , Reyes, Calvin, Reyes, Denise , Robison, Justin , Chen, Stephanie Rossi, Ryan, Laurie, Sachdev, Pallavi, Saito, Naomi , Salazar, Jennifer, Thao, Mai Seng, Shaffer, Elizabeth , Shaw, Leslie M. , Silverberg, Nina, Strong, Joe, Talavera, Sandra , Taylor‐Reinwald, Lisa, Thal, Leon J., Thomas, Lisa , Thompson, Paul , Tosun, Duygu , Trojanowki, John Q., Sacrey, Diana Truran, Villemagne, Victor L. , Walter, Sarah , Wan, Yang , Ward, Chad, Webb, Caitlin, Weiner, Michael W. , Weisensel, Trinity, Zimmerman, Caileigh, Poirier, Judes, Breitner, John C.S. , Badawy, Mohamed , Baril, Andrée‐Ann, Aguilar, Ricardo A, Gorriti, Annabella B, Gispert, Lidia C, Martinez, Alba C, Iglesias, Ruth D, Julian, Sherezade F, Serra, P, González‐Escalante, Armand , Penas, Laura H, Rodriguez, Gema H, Ninou, Jordi H, Gamaz, Laura Iglesias, Knezevic, Iva, Alvarez, Paula M, Diaz, Tania M, Palacios, Eva , Ballester, A, Mendez, Sandra P, Freixedes, Laura Ros, Vila, Aleix S, Harster, Lluis S, Prat, Anna S, Jaramillo, Marc V, Jack, Clifford R , Feizpour, Azadeh , Doré, Vincent , Pichet Binette, Alexa , Salvadó, Gemma , Janelidze, Shorena , Therriault, Joseph , Brum, Wagner Scheeren , Stomrud, Erik , Mattsson, Niklas , Palmqvist, Sebastian , Coomans, Emma M. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Benzinger, Tammie L.S. , Gispert, Juan Domingo , Blennow, Kaj , Alcolea, Daniel , Fortea, Juan , Johnson, Sterling C. , Rosa-Neto, Pedro , Schindler, Suzanne E. , Suárez‐Calvet, Marc , Ossenkoppele, Rik , Hansson, Oskar , Groups, ADNI, ALFA, and PREVENT-AD Study, Aisen, Paul , Barnes, Lisa L. , Beckett, Laurel , Das, Sandhitsu R. , Donohue, Michael , Drake, Erin, Erickson, Claire M. , Fletcher, Evan M. , Arani, Arvin , Foroud, Tatiana , Fox, Nick C. , Frank, Richard, González, Hector, Green, Robert C. , Grill, Joshua D. , Harkins, Kristin , Ho, Carole , Hsiao, John , Jo, Taeho, Kaddurah‐Daouk, Rima , Kantarci, Kejal , Koeppe, Robert A. , Largent, Emily A. , Lee, Edward B. , Lee, Virginia M.‐Y. , Morris, John C. , Nho, Kwangsik T. , Nir, Talia M. , Nudelman, Kelly , Okonkwo, Ozioma, Petersen, Ronald, Rabinovici, Gil D. , Rafii, Michael S. , Reid, Robert, Reyes, Denise, Risacher, Shannon L. , Mindt, Mónica Rivera , Sachdev, Pallavi, Saykin, Andrew J. , Schwarz, Christopher G. , Senjem, Matthew L. , Li, Shen , Smith, Stephanie R. , Snyder, Peter J. , Thomopoulos, Sophia I. , Toga, Arthur W. , Vemuri, Prashanthi , Yushkevich, Paul A. , Badawy, Mohamed, Baillet, Sylvain , Minguillón, Carolina , Brugulat‐Serrat, Anna , Cacciaglia, Raffaele , Campo, Marta del , Pascual, Maria, Rodríguez‐Fernández, Blanca , Vilor‐Tejedor, Natàlia

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1122

10.1001/jamaneurol.2025.3217 | PMID 40952756 Get It

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures Aβ status, determined by CSF or Aβ PET biomarkers. Results Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and Relevance The findings highlight the potential of plasma p-tau217 as a stand-alone test—or when used in a sequential 2-step approach alongside PET or CSF testing—as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments.
A Cross‐Sectional Analysis of Social Determinants of Health in Bipolar Disorder: Exploring Gender‐Related Differences
Gardea‐Resendez, Manuel , Fuentes‐Salgado, Manuel, Romo‐Nava, Francisco , Prieto, Miguel L. , Bond, David J. , Betcher, Hannah K. , Moore, Katherine M. , Solares‐Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Taylor-Desir, Monica , Frye, Mark A. , Solares-Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Sanchez-Ruiz, Jorge A , Singh, Balwinder , Biernacka, Joanna , Taylor-Desir, Monica J., Frye, Mark , Romo-Nava, F , Bond, David J , Gardea-Resendez, Manuel , Özerdem, Ayşegül , Sánchez-Ruiz, Jorge A. , Veldić, Marin , Singh, Balwinder , Cuéllar‐Barboza, Alfredo B. , Coombes, Brandon J. , Biernacka, Joanna M. , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | September 12, 2025 | Volume: 27 | Issue: 8 | Pages: 545-550

10.1111/bdi.70062 | PMID 40936288 Get It

ABSTRACT Objectives To explore the clinical impact of social determinants of health (SDoH) stress in bipolar disorder (BD) course of illness and to explore potential gender differences in SDoH stress endorsement. Methods 2280 individuals living with BD type I or II (62% women; 67.5% BD‐I) participating in the Mayo Clinic Bipolar Biobank who completed a questionnaire assessing positive and negative‐valent stressors in the 12 months prior to study enrollment were included for this analysis. Six negative stressors were used as proxies of SDoH. Generalized linear models were used to test the association between SDoH stressors and markers of illness severity as well as potential differences by sex by including an interaction term. Results After adjusting for age, sex, and recruitment site, SDoH‐related stressors were significantly associated with a more severe course of illness in both men and women. Except for unemployment rates, women reported more frequently SDoH‐related stress (i.e., lack of family support, financial problems, health coverage and access problems). Conclusions The study found significant gender differences in both the endorsement of specific SDoH stressors and in the prevalence of specific illness severity markers; however, it did not directly test the predictive relationship between gender differences in SDoH and illness severity markers. Future studies aiming to achieve health equity in mental health care should continue assessing social determinants of health stressors, incorporating a gender perspective to better understand their influence on bipolar disorder.
Eliminating Disparities in Otolaryngology Resident Application Selection
Bukowski, Emily E. K. , Bisco, Susan E. , Carducci, Valentina , Stokken, Janalee K. , Yin, Linda X , Bayan, Semirra L. , Carlson, Matthew L , Yin, Linda X. , Romero‐Brufau, Santiago

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | September 11, 2025 | Volume: 135 | Issue: 2 | Pages: 101-107

10.1177/00034894251363745 | PMID 40931850 Get It

Objective: To develop, implement, and evaluate a novel process used for residency application review that deemphasizes metrics known to create bias with the goal of interviewing and matching a more diverse resident cohort. Methods: Between 2020 and 2023, a novel standardized rubric and application review process were developed and implemented at the authors’ academic training program. The rubric deemphasized USMLE scores, honor society membership, and number of publications while utilizing an AI-driven pre-sort of applications, facilitating holistic review. This weighted applicant attributes identified in personal statements, life experiences, achievements in community, leadership roles, otolaryngology-specific impressions highlighted in letters of recommendation, and otolaryngology-specific research and publications similarly to academic metrics (clerkship grades and standardized test scores). Demographics of applicants interviewed and matched into our program were compared pre- and post-implementation using descriptive statistics. Results: Using a standardized rubric to review residency applications that deemphasizes traditional metrics, the authors’ otolaryngology residency program has interviewed, ranked, and matched more diverse candidates. As a result, from 2019 to 2022, the overall resident cohort has diversified from 4% historically marginalized residents to 24%, from 28% female residents to 44%, and from 33% of residents outside our geographic region to 66%. Conclusion: There is significant underrepresentation among otolaryngology residents. Selection based upon USMLE Step 1 scores, honor society membership, and number of publications have been shown to restrict diversity. Purposeful holistic review increases diversity in interviewed and matched resident cohort.
Global consensus statement on the management of pregnancy in inflammatory bowel disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie D. , Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B.

Mayo Clinic

Gut | September 9, 2025 | Volume: 75 | Issue: 2 | Pages: 208-251

10.1136/gutjnl-2025-336402 | PMID 40876906 Get It

Background & aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
Moore, Amy , Teras, Lauren R. , Machiela, Mitchell J. , Arias, Joshua , Monnereau, Alain , Wang, Zhaoming , Vermeulen, Roel , Smedby, Karin E. , Spinelli, John J., Nieters, Alexandra , Bracci, Paige M. , Camp, Nicola J. , Hjalgrim, Henrik, Adami, Hans‐Olov , Albanes, Demetrius, Becker, Nikolaus, Benavente, Yolanda , Clavel, Jacqueline , Curtin, Karen , Ghesquières, Hervé, Glimelius, Bengt, Lan, Qing , Liebow, Mark , McKay, James , Offit, Kenneth, Padoan, Marina, Patel, Alpa V. , Ríboli, Elio , Severson, Richard K., Tinker, Lesley F. , Weinstein, Stephanie J. , Zheng, Tongzhang, Chanock, Stephen J., Rothman, Nathaniel , Berndt, Sonja I. , Teras, Lauren R , Wang, Zhaoming , Vajdic, Claire M , De Vivo, Immaculata , Boffetta, Paolo , Brooks-Wilson, Angela R , Canzian, Federico , Southey, Melissa C , Cerhan, James R , Berndt, Sonja I , Clavel, Jacqueline , Machiela, Mitchell J , Riboli, Elio , Kane, Eleanor , Panagiotou, Orestis A. , Doo, Nicole Wong , Slager, Susan L. , Vajdic, Claire M. , Vijai, Joseph , Giles, Graham G. , Link, Brian K. , Arslan, Alan A. , Salles, Gilles , Cozen, Wendy , Vivo, Immaculata De , Albanes, Demetrius , Bisanzi, Simonetta , Brennan, Paul E. , Brooks‐Wilson, Angela , Canzian, Federico , Conde, Lucía , Cox, David G. , Foretová, Lenka , Glimelius, Bengt , Habermann, Thomas M. , Hofmann, Jonathan N. , Lan, Qing , Lincoln, Anne , Maynadié, Marc , Melbye, Mads , Miligi, Lucia , Milne, Roger L. , Molina, Thierry Jo , Morton, Lindsay M. , North, Kari E. , Offit, Kenneth, Piro, Sara , Purdue, Mark P. , Ravichandran, Vignesh , Southey, Melissa C. , Staines, Anthony , Travis, Ruth C. , Wang, Sophia , Weiderpass, Elisabete , Rothman, Nathaniel , Birmann, Brenda M. , Cerhan, James R.

Mayo Clinic

International Journal of Cancer | September 5, 2025 | Volume: 158 | Issue: 1 | Pages: 45-59

10.1002/ijc.70039 | PMID 40910475 Get It

Abstract Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome‐wide association studies of European ancestry ( N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist‐to‐hip ratio (WHR), and waist‐to‐hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05–1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR per SD = 1.12, 95% CI: 1.02–1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
Bergsland, Emily K. , Geyer, Susan, Asmis, Timothy R., Behr, Spencer C. , Kuebler, J. Philip , Kumthekar, Priya , Mazza, Gina L. , Maitland, Michael L. , Niedzwiecki, Donna , Nixon, Andrew B. , Schwartz, Lawrence H., Meyerhardt, Jeffrey A. , Schwartz, Lawrence H. , Mazza, Gina L , Strosberg, Jonathan R , Venook, Alan P , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Nixon, Andrew B , Niedzwiecki, Donna , Schwartz, Lawrence H , Kuebler, Philip , Strosberg, Jonathan , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 3, 2025 | Volume: 43 | Issue: 29 | Pages: 3170-3183

10.1200/jco-24-02644 | PMID 40902132 Get It

PURPOSE Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, PDGFR-alpha and-beta, and c-Kit, was tested for efficacy in epNET. PATIENTS AND METHODS We conducted a multicenter, randomized, double-blind, phase II study of pazopanib (800 mg once daily) versus placebo in low- to intermediate-grade epNET with radiologic progressive disease (PD) within 12 months of study entry. Previous somatostatin analog (SSA) was required for midgut tumors, and concurrent SSA was allowed. The primary end point was progression-free survival (PFS) by blinded independent central review. Unblinding and crossover were allowed if PD was confirmed by central review. RESULTS One hundred seventy-one patients (97 pazopanib and 74 placebo) were randomly assigned between September 2013 and October 2015. The majority had a midgut primary site (75%) and previous SSA treatment (93%). About half (49%) of the patients had functional tumors. The median follow-up was 61 months (95% CI, 60 to 63). Median PFS was 11.8 versus 7.6 months in pazopanib versus placebo, respectively (hazard ratio, 0.54 [95% CI, 0.37 to 0.79]; P < .001); 49 placebo patients crossed over to pazopanib. There was no significant difference in overall survival between the treatment arms. Rates of grade 3 or greater adverse events (regardless of attribution) were higher in pazopanib versus placebo (84% v 47%; P < .001), as were grade 5 death events (8% v 0%, P = .017). CONCLUSION Pazopanib compared with placebo significantly improves PFS in patients with progressive epNET, confirming that the VEGF signaling pathway is a valid target for therapy in epNET. However, after integrating the associated risks relative to the benefits, further development of pazopanib in this clinical context is not planned.
Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia
Cabrera-Serrano, Antonio José , Rodríguez‐Sevilla, Juan José , Reyes‐Zurita, Fernando J. , Collado, Rosa , Puiggros, Anna, Cornejo-Calvo, Elena , Horst, Rob ter , Benavente, Yolanda , Jerez, Andrés , Ramos‐Campoy, Sílvia , González‐Olmedo, Carmen , Jannus, Fatin , Marcos‐Gragera, Rafael , Carretero-Fernández, María, Sampaio‐Marques, Belém , Gámez, Irene, García‐Álvarez, María , Camp, Nicola J. , Kamaso, Joanna, Pérez, Eva María, Alcoceba, Miguel , Campa, Daniele , Sanjosé, Sílvia de , Netea, Mihai G. , McKay, James, Casabonne, Delphine , Berndt, Sonja I. , Sáinz, Juan , Rodríguez-Sevilla, Juan José , Reyes-Zurita, Fernando Jesús , Collado, Rosa , Cornejo-Calvo, Elena , Ter Horst, Rob , Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López-Nevot, Miguel Ángel , Ramos-Campoy, Silvia , Chen-Liang, Tzu-Hua , Jannus, Fatin , Marcos-Gragera, Rafael , Carretero-Fernández, María , Sampaio-Marques, Belém , Camp, Nicola J , Dierssen-Sotos, Trinidad , Kamaso, Joanna , Li, Yang , Marasca, Roberto , Ludovico, Paula , Canzian, Federico , Casabonne, Delphine , Berndt, Sonja I , Slager, Susan L , Sainz, Juan , Alcoceba, Miguel , Sánchez‐Maldonado, José Manuel , Puiggros, Anna , García-Martín, Paloma, Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López‐Nevot, Miguel Ángel , Moreno, Vı́ctor , Dierssen‐Sotos, Trinidad , Norman, Aaron D. , Luppi, Mario , Li, Yang , Marasca, Roberto , Ludovico, Paula , Clay‐Gilmour, Alyssa , Canzian, Federico , Ibáñez, Mariam , McKay, James , Slager, Susan L. , Netea, M. G.

Mayo Clinic

Blood Advances | September 3, 2025 | Volume: 9 | Issue: 23 | Pages: 6076-6089

10.1182/bloodadvances.2025017345 | PMID 40902075 Get It

Abstract We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.